# Curebase

> Curebase is a San Francisco-based eClinical software company building an AI-powered platform that runs clinical trials around patients' lives instead of inside hospital walls. Its single system spans study startup to database lock - combining electronic data capture (EDC), eConsent, ePRO/eCOA, patient recruitment, and a virtual research site model - so sponsors can launch decentralized and hybrid trials faster, capture cleaner data, and reach more diverse participant populations.

- **Founded:** 2017
- **Headquarters:** San Francisco, United States
- **Founders:** Tom Lemberg (Founder & CEO)
- **Team size:** ~55 employees
- **Products:** EDC (Electronic Data Capture), eConsent, ePRO / eCOA, Patient Recruitment & Engagement, Sitebase / Virtual Research Site
- **Notable:** Raised $40M Series B in 2022, led by Industry Ventures with strategic investment from Gilead Sciences, Founder Tom Lemberg named to Forbes 30 Under 30 (2022) for healthcare impact, Completed 50+ clinical studies across the US, Canada, UK, and France

## Products & services

- **EDC (Electronic Data Capture)** — Clinical-grade data capture system unifying study data across decentralized and hybrid trial sites.
- **eConsent** — Electronic informed consent that lets participants enroll and consent remotely, compliant with 21 CFR Part 11.
- **ePRO / eCOA** — Electronic patient-reported outcomes and clinical outcome assessments captured remotely via app.
- **Patient Recruitment & Engagement** — Tools to find, enroll, and retain participants - including diverse and previously untapped populations.
- **Sitebase / Virtual Research Site** — A virtual site model with trained principal investigators overseeing studies, plus a 'bring your own physician' option.
- **AI for Clinical Trials** — AI-driven patient matching and trial insights layered across the eClinical platform.
- **Trial Execution Services** — End-to-end site and trial execution packages, including an all-in-one bundle for digital therapeutics (DTx) sponsors.

## Achievements

- Raised $40M Series B in 2022, led by Industry Ventures with strategic investment from Gilead Sciences
- Founder Tom Lemberg named to Forbes 30 Under 30 (2022) for healthcare impact
- Completed 50+ clinical studies across the US, Canada, UK, and France
- Y Combinator alum (2018)
- SOC 2 Type II certified and GDPR compliant
- Launched first one-stop-shop DCT platform bundled with trial execution services for the digital therapeutics market (2023)

## Latest updates

- **2022-05** — Raised $40M Series B led by Industry Ventures, with strategic investment from Gilead Sciences.
- **2022-11** — Partnered with BEKHealth to use AI-powered patient matching for decentralized trial recruitment.
- **2023-01** — Launched an all-in-one software and trial execution package for digital therapeutics (DTx) companies.
- **2025** — Repositioned as an AI-powered eClinical platform spanning study startup to database lock, under the curebase.ai domain.

## Links

- Website: https://curebase.ai
- LinkedIn: https://www.linkedin.com/company/curebase
- Twitter/X: https://twitter.com/CurebaseDCT
- Facebook: https://facebook.com/curebase2020/?ref=page_internal

---

Profile page: https://yespress.io/curebase
Published by YesPress — https://yespress.io
Last updated: 2026-06-15